# Operational Summary 

for the Fiscal Year Ended March 31, 2009

May 12, 2009
Mitsubishi Chemical Holdings Corporation

## Table of Contents

| Consolidated Financial Statements for FY2008 | Page No. | Consolidated Financial Statements Forecasts for FY2009 | Page No. |
| :---: | :---: | :---: | :---: |
| Statements of Operations | 3 | Statements of Operations | 12 |
| Net Sales by Business Segments | 4 | Net Sales by Business Segments | 13 |
| Operating Income by Business Segments | 5 | Operating Income by Business Segments | 14 |
| Operating Analysis (Chemicals Segment) | 6 | Operating Analysis (FY2008 vs. FY2009) | 15 |
| Operating Analysis (Polymers Segment) | 7 | Operating Income by Business Segments (1st Half and 2nd Half) | 16 |
| Extraordinary Gain (Loss) | 8 | Operating Analysis (1st Half vs. 2nd Half) | 17 |
| Major Subsidiaries | 9 | Major Subsidiaties | 18 |
| Balance Sheets | 10 | Cash Dividends | 19 |
| Cash Flows | 11 |  |  |
|  |  | Reference Materials (Consolidated) | $\begin{gathered} \text { Page } \\ \text { No. } \end{gathered}$ |
|  |  | Number of Affiliates | 20 |
|  |  | Financial Position | 21 |
|  |  | Capital Expenditure, Depreciation \& Amortization, R\&D Expenses, Total Assets, and Number of Employees by Business Segments | 22 |
| Notes: |  |  |  |
| FY2007: April 1, 2007 - March 31, 2008 |  |  |  |
| FY2008: April 1, 2008 - March 31, 2009 |  |  |  |
| $\begin{aligned} & \text { 1Q of FY2008: April 1, 2008 - June 30, } 2008 \\ & \text { 2Q of FY2008: July 1, } 2008 \text { - September 30, } 2008 \\ & \text { 3Q of FY2008: October 1, } 2008 \text { - December 31, } 2008 \\ & \text { 4Q of FY2008: January 1, } 2009 \text { - March 31, } 2009 \end{aligned}$ | $\left.\begin{array}{l} \} \\ \} \end{array}\right\}$ | First Half of FY2008 |  |

## Consolidated Statements of Operations



| Change in accounting standards included in operating income | FY2008 |
| :---: | ---: |
| Inventory valuation method | $(6.6)$ |
| Useful life of machinary and equipment | $(2.8)$ |
| Total | $(9.4)$ |

## Consolidated Net Sales by Business Segments

|  | FY2008 | FY2007 | Change | Analysis of Changes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Sales Price | Sales Volume | Others |
| Total | 2,909.0 | 2,929.8 | (20.8) | 83.0 | (291.0) | 187.0 |
| Electronics Applications | 327.5 | 404.4 | (76.9) | (28.0) | (35.0) | (14.0) |
| Designed Materials | 276.5 | 295.7 | (19.2) | 7.0 | (26.0) | 0.0 |
| Health Care | 497.1 | 395.8 | 101.3 | (14.0) | 21.0 | 94.0 |
| Chemicals | 1,075.0 | 1,170.2 | (95.2) | 91.0 | (132.0) | (54.0) |
| Polymers | 573.0 | 467.7 | 105.3 | 24.0 | (80.0) | 161.0 |
| Others | 159.9 | 196.0 | (36.1) | 3.0 | (39.0) | 0.0 |

## Consolidated Operating Income by Business Segments

|  | FY2008 | FY2007 | Change | Analysis of Changes |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Price | Volume | Fixed Costs | Others |
| Total | 8.2 | 125.0 | (116.8) | (52.0) | (39.0) | (9.0) | (17.0) |
| Electronics Applications | 4.8 | 31.6 | (26.8) | (9.0) | (18.0) | 1.0 | (1.0) |
| Designed Materials | (2.1) | 9.7 | (11.8) | (1.0) | (7.0) | (4.0) | 0.0 |
| Health Care | 79.3 | 57.2 | 22.1 | (13.0) | 13.0 | 4.0 | 18.0 |
| Chemicals | (55.5) | 10.9 | (66.4) | (23.0) | (9.0) | (7.0) | (27.0) |
| Polymers | (13.0) | 11.2 | (24.2) | (5.0) | (12.0) | 0.0 | (7.0) |
| Others | 8.8 | 14.1 | (5.3) | (1.0) | (6.0) | 1.0 | 0.0 |
| Corporate | (14.1) | (9.7) | (4.4) | 0.0 | 0.0 | (4.0) | 0.0 |


| Price Dilions of Yen)  |  |
| ---: | ---: |
| Sales <br> Price | Purchase <br> Price |
| 83.0 | $(135.0)$ |
| $(28.0)$ | 19.0 |
| 7.0 | $(8.0)$ |
| $(14.0)$ | 1.0 |
| 91.0 | $(114.0)$ |
| 24.0 | $(29.0)$ |
| 3.0 | $(4.0)$ |
| 0.0 | 0.0 |

## Analysis of Operating Income (FY2007 vs. FY2008): Chemicals Segment



Analysis of Operating Income (FY2007 vs. FY2008): Polymers Segment


## Consolidated Extraordinary Gain (Loss)

|  | (Billions of Yen) |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2008 | FY2007 | Change |
| Total | (42.1) | 88.9 | (131.0) |
| Extraordinary gain | 14.8 | 123.3 | (108.5) |
| Gain on sales of fixed assets Gain on changes in equity of affiliated compnies Others | $\begin{gathered} 9.5 \\ 5.3 \end{gathered}$ | $\begin{array}{r} 118.1 \\ 5.2 \end{array}$ | $\begin{array}{r\|} \hline 9.5 \\ (118.1) \\ 0.1 \end{array}$ |
| Extraordinary loss | (56.9) | (34.4) | (22.5) |
| Loss on revaluation of investments in securities | (11.5) | (0.2) | (11.3) |
| Loss on impairment of fixed assets | (11.4) | (1.9) | (9.5) |
| Provision for loss of litigation | (8.8) | (9.5) | 0.7 |
| Loss on cancellation of raw material purchase contract | (5.0) |  | (5.0) |
| Special severance payments for early retired employees | (4.3) | (1.3) | (3.0) |
| Charges of cartel | (3.7) |  | (3.7) |
| Loss on disposal of fixed assets | (3.4) | (4.6) | 1.2 |
| Others | (8.8) | (16.9) | 8.1 |

## Major Subsidiaries

| Company | Segment | Net Sales (Billions of Yen) |  | Operating Income (vs. FY2007) |
| :---: | :---: | :---: | :---: | :---: |
|  |  | FY2008 | FY2007 |  |
| Mitsubishi Chemical Corporation (Consolidated) |  | 2,216.9 | 2,271.6 | $\sum$ |
| Mitsubishi Kagaku Media Co., Ltd. and Verbatim Corporation Group | Electronics Applications | 81.4 | 92.3 | S |
| Nippon Kasei Chemical Co., Ltd. (Consolidated) | Electronics Applications | 48.6 | 51.7 | $S$ |
| Mitsubishi Kagaku Imaging Corporation | Electronics Applications | 18.3 | 14.1 | $\pi$ |
| Clinical testing and investigation Business Group*1 | Health Care | 81.2 | 79.4 | $\checkmark$ |
| PT. Mitsubishi Chemical Indonesia MCC PTA India Corp. Private Limited Ningbo Mitsubishi Chemical Co., Ltd. DIA Terephthalic Acid Corporation | Chemicals | 185.2 | 205.4 | $\Sigma$ |
| The Kansai Coke and Chemicals Co., Ltd. | Chemicals | 141.5 | 72.3 | $\Delta$ |
| Japan Polypropylene Corporation | Polymers | 206.8 | 205.4 | $\underline{y}$ |
| Japan Polyethylene Corporation *2 | Polymers | 178.4 | (170.2) | $\sum$ |
| Mitsubishi Chemical Logistics Corporation | Others | 87.7 | 92.2 | $\sum$ |
| Mitsubishi Chemical Engineering Corporation | Others | 154.4 | 184.9 | $S$ |
| Mitsubishi Tanabe Pharma Corporation (Consolidated) | Health Care | 414.8 | ${ }^{* 3} 315.6$ | $\begin{gathered} \hline 54.0 \rightarrow 71.7 \\ 17.7 \\ \hline \end{gathered}$ |
| Mitsubishi Plastics, Inc. (Consolidated) | Electronics Applications Designed Materials | 346.2 | 400.4 | S |

* 1 In case of simple totals of Mitsubishi Chemical Medience Corporation, Mitsubishi Kagaku Iatron, Inc., Mitsubishi Chemical Safety Institute Ltd.
*2 New consolidated subsidiary
* 3 Included Tanabe Seiyaku's net sales in the first half of FY2007: net sales, $¥ 409.4$ billion yen; operating income, $¥ 72.5$. billion yen.


## Consolidated Balance Sheets

| Debitor | March 31, 2009 | March 31, 2008 | Change |
| :--- | ---: | ---: | ---: |
| Cash and deposits | 96.4 | 116.1 | $(19.7)$ |
| Inventories | 463.3 | 427.1 | 36.2 |
| Trade receivables | 499.7 | 599.9 | $(100.2)$ |
| Others | 265.3 | 181.8 | 83.5 |
| Current assets | $1,324.7$ | $1,324.9$ | $(2.2)$ |
| Fixed assets | 947.3 | 972.0 | $(24.7)$ |
| Investment and others | 468.9 | 468.9 | 0.0 |
| Fixed assets | $1,416.2$ | $1,440.9$ | $(24.7)$ |
| Total assets | $2,740.9$ | $2,765.8$ | $(24.9)$ |


| Creditor | March 31, 2009 | March 31, 2008 | Change |
| :--- | ---: | ---: | ---: |
| Interest-bearing debts | $1,033.2$ | 822.5 | 210.7 |
| Trade payables | 368.0 | 435.1 | $(67.1)$ |
| Others | 399.6 | 412.3 | $(12.7)$ |
| Liabilities | $1,800.8$ | $1,669.9$ | 130.9 |
| Shareholders' equity | 692.3 | 781.6 | $(89.3)$ |
| Valuation and others | $(23.3)$ | 46.2 | $(69.5)$ |
| Minorities interests | 271.1 | 268.1 | 3.0 |
| Net assets | 940.1 | $1,095.9$ | $(155.8)$ |
| Total liabilities and net assets | $2,740.9$ | $2,765.8$ | $(24.9)$ |


|  | March 31, 2009 | March 31, 2008 | Change |  |  |
| :--- | ---: | ---: | ---: | :---: | :---: |
| Interest-bearing debts (incl. notes) | $1,033.8$ | 823.1 | 210.7 |  |  |
| Debt-equity ratio | 1.6 | 1.0 | 0.6 |  |  |
| Net debt-equity ratio | 1.1 | 0.8 | 0.3 |  |  |
|  |  |  |  |  |  |
| Shareholders' equity (*1) | 669.0 | 827.8 | $(158.8)$ |  |  |
| Shareholders' equity ratio | $24.4 \%$ | $29.9 \%$ | $(5.5 \%)$ |  |  |

(*1) Net assets -minority interests-stock warrant

## Consolidated Statements of Cash Flows



## Consolidated Statements of Operations (FY2009 Forecast)

|  |  <br> Exchange rate (¥/US\$) <br> Naphtha price ( $¥ / \mathrm{KI})$ |  | FY2009 <br> Forecast <br> 95 <br> 36,000 | $\begin{array}{r\|} \text { FY2008 } \\ \hline 103 \\ \hline 58,800 \\ \hline \end{array}$ |  | (Billions of Yen) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | FY2008 <br> Acutual |  |  |  |
|  | FY2009 Forecast |  |  |  | Change | FY2009 Forecast |  |
|  | 1st Half | 2nd Half | Full Year |  |  | 1Q | 2Q |
| Net sales | 1,160.0 | 1,340.0 | 2,500.0 | 2,909.0 | (409.0) | 570.0 | 590.0 |
| Operating income | (10.0) | 75.0 | 65.0 | 8.2 | 56.8 | (23.0) | 13.0 |
| Income (expenses) on financing activities <br> Other non-operating income (expenses) <br> Equity in earnings of non-consolidated subsidiaries and affiliates | $\begin{gathered} \hline(5.0) \\ (9.0) \\ 1.0 \\ \hline \end{gathered}$ | (5.0) <br> (8.0) <br> 2.0 | $(10.0)$ <br> $(17.0)$ <br> 3.0 | $(3.2)$ <br> $(1.8)$ <br> $(5.1)$ | $(6.8)$ <br> $(15.2)$ <br> 8.1 | $(2.0)$ <br> $(6.0)$ <br> 0.0 | (3.0) <br> (3.0) <br> 1.0 <br> 8.0 |
| Ordinary income | (23.0) | 64.0 | 41.0 | (1.9) | 42.9 | (31.0) | 8.0 |
| Extraordinary gain <br> Extraordinary loss | $\begin{gathered} \hline 2.0 \\ (3.0) \\ \hline \end{gathered}$ | $\begin{gathered} 2.0 \\ (15.0) \end{gathered}$ | $\begin{array}{c\|} \hline 4.0 \\ (18.0) \\ \hline \end{array}$ | $\begin{gathered} 14.8 \\ (56.9) \end{gathered}$ | $\begin{gathered} \hline(10.8) \\ 38.9 \\ \hline \end{gathered}$ | 2.0 <br> 0.0 | 0.0 <br> $(3.0)$ |
| Income before income taxes | (24.0) | 51.0 | 27.0 | (44.0) | 71.0 | (29.0) | 5.0 |
| Current and deferred income taxes Minority interests in consolidated subsidiaries | $\begin{gathered} \hline 1.0 \\ (2.0) \end{gathered}$ | $\begin{aligned} & \hline(18.0) \\ & (17.0) \end{aligned}$ | $\begin{aligned} & \hline(17.0) \\ & (19.0) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline(12.4) \\ & (10.8) \end{aligned}$ | (4.6) <br> $(8.2)$ | 1.0 3.0 | 0.0 $(5.0)$ |
| Net income | (25.0) | 16.0 | (9.0) | (67.2) | 58.2 | (25.0) | 0.0 |

## Consolidated Net Sales by Business Segments (FY2009 Forecast)

|  | FY2009 <br> Forcast | $\begin{gathered} \hline \text { FY2008 } \\ \text { Actual } \end{gathered}$ | Change | Analysis of Changes |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Sales Price | Sales Volume | Others |
| Total | 2,500.0 | 2,909.0 | (409.0) | (490.0) | 56.0 | 25.0 |
| Electronics Applications | 320.0 | 327.5 | (7.5) | (14.0) | 6.0 | 0.0 |
| Designed Materials | 280.0 | 276.5 | 3.5 | (9.0) | 13.0 | 0.0 |
| Health Care | 520.0 | 497.1 | 22.9 | (1.0) | 24.0 | 0.0 |
| Chemicals | 730.0 | 1,075.0 | (345.0) | (298.0) | (9.0) | (38.0) |
| Polymers | 500.0 | 573.0 | (73.0) | (164.0) | 28.0 | 63.0 |
| Others | 150.0 | 159.9 | (9.9) | (4.0) | (6.0) | 0.0 |

## Consolidated Operating Income by Business Segments (FY2009 Forecast)

|  | FY2009 Forcast | FY2008 Actual | Change | Analysis of Chages |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | Price | Volume | Fixed Costs | Others |
| Total | 65.0 | 8.2 | 56.8 | 50.0 | 13.0 | (16.0) | 10.0 |
| Electronics Applications | 10.0 | 4.8 | 5.2 | (4.0) | 9.0 | 0.0 | 0.0 |
| Designed Materials | 7.0 | (2.1) | 9.1 | 4.0 | 4.0 | 1.0 | 0.0 |
| Health Care | 72.0 | 79.3 | (7.3) | (1.0) | 9.0 | (15.0) | 0.0 |
| Chemicals | (2.0) | (55.5) | 53.5 | 26.0 | 3.0 | (1.0) | 26.0 |
| Polymers | (9.0) | (13.0) | 4.0 | 26.0 | (4.0) | (2.0) | (16.0) |
| Others | 1.0 | 8.8 | (7.8) | (1.0) | (8.0) | 1.0 | 0.0 |
| Corporate | (14.0) | (14.1) | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |


| Analysis of Differences <br> Sales <br> PricePurchase <br> Price |  |
| ---: | ---: |
| $(490.0)$ | 540.0 |
| $(14.0)$ | 10.0 |
| $(9.0)$ | 13.0 |
| $(1.0)$ | 0.0 |
| $(298.0)$ | 324.0 |
| $(164.0)$ | 190.0 |
| $(4.0)$ | 3.0 |
| 0.0 | 0.0 |

## Operating Analysis (FY2008 Actual vs. FY2009 Forecast)



## Consolidated Operating Income by Business Segments (1st Half and 2nd Half of FY2009 Forecast)

|  | FY2009 Forecast |  |  |  | FY2009 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1st Half (1) | 2nd Half (2) | Full Year | (2) - (1) | 19 | 2 Q |
| Total | (10.0) | 75.0 | 65.0 | 85.0 | (23.0) | 13.0 |
| Electronics Applications | (1.0) | 11.0 | 10.0 | 12.0 | (2.0) | 1.0 |
| Designed Materials | 0.0 | 7.0 | 7.0 | 7.0 | (1.0) | 1.0 |
| Health Care | 26.0 | 46.0 | 72.0 | 20.0 | 11.0 | 15.0 |
| Chemicals | (9.0) | 7.0 | (2.0) | 16.0 | (6.0) | (3.0) |
| Polymers | (19.0) | 10.0 | (9.0) | 29.0 | (22.0) | 3.0 |
| Others | 0.0 | 1.0 | 1.0 | 1.0 | 0.0 | 0.0 |
| Corporate | (7.0) | (7.0) | (14.0) | 0.0 | (3.0) | (4.0) |
| Inventory valuation gain | (22.0) | (1.0) | (23.0) | 21.0 | (16.0) | (6.0) |
| Chemicals (Petrochemicals) | 4.0 | 0.0 | 4.0 | (4.0) | 4.0 | 0.0 |
| Chemicals (Carbon) | (4.0) | (1.0) | (5.0) | 3.0 | (3.0) | (1.0) |
| Polymers | (22.0) | 0.0 | (22.0) | 22.0 | (17.0) | (5.0) |
| Change method of inventory valuation | 2.0 | 8.0 | 10.0 | 6.0 | (8.0) | 10.0 |
| Chemicals (Petrochemicals) | 4.0 | 0.0 | 4.0 | (4.0) | 4.0 | 0.0 |
| Chemicals (Carbon) | (3.0) | 5.0 | 2.0 | 8.0 | (3.0) | 0.0 |
| Polymers | 1.0 | 3.0 | 4.0 | 2.0 | (9.0) | 10.0 |

## Operating Analysis

(1st Half vs. 2nd Half of FY2009 Forecast)


## Major Subsidiaries (FY2009 Forecast)

| Company | Segment | Net Sales (Billions of Yen) |  | Operating Income <br> (vs. FY2008) |
| :---: | :---: | :---: | :---: | :---: |
|  |  | FY2009 <br> Forecast | FY2008 <br> Actual |  |
| Mitsubishi Chemical Corporation (Consolidated) |  | 1,830.2 | 2,216.9 | $\checkmark$ |
| Mitsubishi Kagaku Media Co., Ltd. and Verbatim Corporation Group | Electronics Applications | 79.3 | 81.4 | $\checkmark$ |
| Nippon Kasei Chemical Co., Ltd. (Consolidated) | Electronics Applications | 40.0 | 48.6 | $\pi$ |
| Mitsubishi Kagaku Imaging Corporation | Electronics Applications | 20.2 | 18.3 | $\checkmark$ |
| Clinical testing and investigation Business Group | Health Care | 78.6 | ${ }^{* 1} 81.2$ | $\checkmark$ |
| PT. Mitsubishi Chemical Indonesia MCC PTA India Corp. Private Limited Ningbo Mitsubishi Chemical Co., Ltd. DIA Terephthalic Acid Corporation | Chemicals | 170.0 | 185.2 | $\hbar$ |
| The Kansai Coke and Chemicals Co., Ltd. | Chemicals | 101.8 | 141.5 | $\pi$ |
| Japan Polypropylene Corporation | Polymers | 173.5 | 206.8 | S |
| Japan Polyethylene Corporation | Polymers | 151.1 | 178.4 | $\sum$ |
| Mitsubishi Chemical Logistics Corporation | Others | 80.1 | 87.7 | $\sum$ |
| Mitsubishi Chemical Engineering Corporation | Others | 70.2 | 154.4 | $\underline{y}$ |
| Mitsubishi Tanabe Pharma Corporation (Consolidated) | Health Care | 408.0 | 414.8 | $\begin{gathered} 71.7 \rightarrow 63.5 \\ (8.2) \end{gathered}$ |
| Mitsubishi Plastics, Inc. (Consolidated) | Electronics Applications Designed Materials | 328.6 | 346.2 | $\pi$ |

## Cash Dividends

|  |  | FY2009 <br> Forecast | FY2008 | FY2007 |
| :---: | :---: | :---: | :---: | :---: |
| Cash dividends per share (Yen) | 1st half | 4 | 8 | 8 |
|  | Year end | 4 | 4 | 8 |
|  | Total | 8 | 12 | 16 |
| Total of cash dividends (Billions of yen) | 1st half | - | 11.0 | 11.0 |
|  | Year end | - | 5.5 | 11.0 |
|  | Total | - | 16.5 | 22.0 |
| Net profit per share (Yen) | Year end | (6.53) | (48.81) | 119.51 |
| Dividend pay out ratio (Consolidated) | Total | - | - | 13.4\% |

Mitsubishi Chemical Holdings Corporation's basic policy is to pay dividends on the levels of our results of operations while considering other factors such as our aim to pay stable dividends over the medium- to long-term and our need to strengthen earnings as resources for future business development.

## Consolidated Affiliated Companies

|  | FY2008 | FY2007 | Difference |
| :---: | ---: | ---: | ---: |
| Consolidated subsidiaries | 177 | 189 | $(12)$ |
| Japan | 95 | 106 | $(11)$ |
| Overseas | 82 | 83 | $(1)$ |
| Affiliates accounted for by the equity method | 63 | 71 | $(8)$ |
| Total | 240 | 260 | $(20)$ |

## Consolidated Financial Position

Total Assets
Shareholders' equity Interest-bearing debt
(Billions of Yen)


Ratio of shareholders' equity to total assets
Debt-equity ratio
Net Debt-equity ratio


## Consolidated Capital Expenditure, Depreciation \& Amortization,

 R\&D Expenses, Total Assets, and Number of Employees by Business Segments|  | Capital Expenditure |  | Depreciation \& Amortization |  | R\&D Expenses |  | Total Assets | Number of Employees |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2009 Forecast | FY2008 Actual | FY2009 Forecast | FY2008 Actual | FY2009 Forecast | FY2008 Actual | FY2008 Actual | FY2008 Actual |
| Electronics Applications | 13.0 | 26.2 | 22.0 | 22.2 | 10.0 | 11.7 | 279.5 | 6,978 |
| Designed Materials | 12.0 | 12.9 | 16.0 | 15.4 | 7.0 | 5.7 | 219.4 | 4,730 |
| Health Care | 20.0 | 19.8 | 24.0 | 20.5 | 95.0 | 83.6 | 817.6 | 13,460 |
| Chemicals | 31.0 | 44.0 | 38.0 | 36.9 | 5.0 | 4.9 | 670.6 | 5,306 |
| Polymers | 13.0 | 22.9 | 23.0 | 15.4 | 12.0 | 8.5 | 419.3 | 4,137 |
| Others | 7.0 | 4.8 | 5.0 | 3.8 | 0.0 | 0.2 | 307.8 | 6,022 |
| Corporate | 8.0 | 8.4 | 4.0 | 5.0 | 13.0 | 13.2 | 26.7 | 847 |
| Total | 104.0 | 139.0 | 132.0 | 119.2 | 142.0 | 127.8 | 2,740.9 | 41,480 |

## Forward-looking Statements

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control. Actual results could differ materially due to numerous factors, including without limitation, market conditions and the effects of industry competition.

